Clinico-Epidemiological Study of Pancreatic, Gall Bladder and Biliary Tract Cancers at Clinical Oncology Department Tanta University Hospitals

Abstract

Background: In Egypt, pancreatic cancer (PC) is the 11th most prevalent malignancy and represents 2.2% of all cancers. PCs cause 3.2% of cancer deaths, ranking 8th. Gall bladder cancers represents about 0.70% of malignancies in Egypt, accounting for 0.77% of cancer deaths. In Gharbia governorate, Gall bladder cancers account for 0.8% and 0.7%, of male malignancies females, respectively. Aim: The aims of this retrospective study is to determine the incidence of pancreatic, gall bladder and biliary tract cancers (BTCs), describe the clinico-pathological pattern of pancreatic, gall bladder and BTCs, and detect progression free survival (PFS), disease free survival (DFS), and overall survival (OS) in correlation with the prognostic factors. Patients and Methods: This retrospective hospital-based clinico-epidemiological study was carried out on 299 patients who were histo-pathological proved pancreatic or biliary tract malignancies through the period from Jan 2015 to Dec 2020 at Clinical Oncology Department Tanta university Hospital, Egypt. Results: The estimated median OS for PC patients was 8 months which was statistically significant better in patients with T1/2, N0, M0 and curative surgical resection, while the estimated median PFS was 4 months with statistically significant better in patients with initial low CA19.9 (<37 U/ml) and in pancreatic body site and the estimated median DFS was 7 months with statistically significant better in N0 and initial low CA19.9 (<37U/ml). As regard BTC, the estimated median OS was 12 months with statistically significant better in patients with T1/2, N0, M0 and grade 2 tumors, the estimated median PFS was 3 with statistically significant better in patients with T1/2, N0, M0, low initial CA19.9 (<37U/ml) and ampulla of vater site while the estimated median DFS was 5 months with statistically significant better in patients with N0. Conclusions: We advocate for the use of genetic counselling to educate families about specific genetic disorders, the risks and advantages, disease management, and potential treatment choices. Multidisciplinary working groups should be established for adequate management.